Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2011 Feb 9

PMID 21300963

Citations 95

Authors

Thomas J Wang

Affiliations

Soon will be listed here.

Citing Articles

Artificial Intelligence in Ischemic Heart Disease Prevention.

Parsa S, Shah P, Doijad R, Rodriguez F Curr Cardiol Rep. 2025; 27(1):44.

PMID: 39891819 DOI: 10.1007/s11886-025-02203-0.

Optical coherence tomography angiography in cardiovascular disease.

Runsewe O, Srivastava S, Sharma S, Chaudhury P, Tang W Prog Cardiovasc Dis. 2024; 87:60-72.

PMID: 39442597 PMC: 11611605. DOI: 10.1016/j.pcad.2024.10.011.

Unveiling TIMPs: A Systematic Review of Their Role as Biomarkers in Atherosclerosis and Coronary Artery Disease.

Aminuddin A, Samah N, Vijakumaran U, Che Roos N, Mohd Nor F, Wan Razali W Diseases. 2024; 12(8).

PMID: 39195176 PMC: 11353419. DOI: 10.3390/diseases12080177.

Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.

Griffiths M, Simpson C, Yang J, Vaidya D, Nies M, Brandal S Chest. 2024; 166(6):1511-1531.

PMID: 39154795 PMC: 11736302. DOI: 10.1016/j.chest.2024.06.3824.

Risk estimation for the primary prevention of cardiovascular disease: considerations for appropriate risk prediction model selection.

van Daalen K, Zhang D, Kaptoge S, Paige E, Di Angelantonio E, Pennells L Lancet Glob Health. 2024; 12(8):e1343-e1358.

PMID: 39030064 PMC: 11283887. DOI: 10.1016/S2214-109X(24)00210-9.

References

Manolio T . Novel risk markers and clinical practice. N Engl J Med. 2003; 349(17):1587-9. DOI: 10.1056/NEJMp038136. View

Wang T . Multiple biomarkers for predicting cardiovascular events: lessons learned. J Am Coll Cardiol. 2010; 55(19):2092-5. DOI: 10.1016/j.jacc.2010.02.019. View

Chan S, Mancini G, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A . The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003; 42(6):1037-43. DOI: 10.1016/s0735-1097(03)00927-6. View

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

Helfand M, Buckley D, Freeman M, Fu R, Rogers K, Fleming C . Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(7):496-507. DOI: 10.7326/0003-4819-151-7-200910060-00010. View

McKeown P, Merlini P, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M . Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009; 41(3):334-41. PMC: 2681011. DOI: 10.1038/ng.327. View

Hoering A, LeBlanc M, Crowley J . Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res. 2008; 14(14):4358-67. PMC: 2569946. DOI: 10.1158/1078-0432.CCR-08-0288. View

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

Bots M, Evans G, Riley W, Grobbee D . Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke. 2003; 34(12):2985-94. DOI: 10.1161/01.STR.0000102044.27905.B5. View

10.

Mulherin S, Miller W . Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med. 2002; 137(7):598-602. DOI: 10.7326/0003-4819-137-7-200210010-00011. View

11.

Vasan R . Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113(19):2335-62. DOI: 10.1161/CIRCULATIONAHA.104.482570. View

12.

Modena M, Bonetti L, Coppi F, Bursi F, Rossi R . Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002; 40(3):505-10. DOI: 10.1016/s0735-1097(02)01976-9. View

13.

Greenland P, Smith Jr S, Grundy S . Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001; 104(15):1863-7. DOI: 10.1161/hc4201.097189. View

14.

Morrow D, de Lemos J . Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115(8):949-52. DOI: 10.1161/CIRCULATIONAHA.106.683110. View

15.

Patterson C, Smith A, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G . The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis. 2009; 209(2):551-7. DOI: 10.1016/j.atherosclerosis.2009.09.030. View

16.

Simon R . The use of genomics in clinical trial design. Clin Cancer Res. 2008; 14(19):5984-93. DOI: 10.1158/1078-0432.CCR-07-4531. View

17.

Pletcher M, Tice J, Pignone M, Browner W . Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004; 164(12):1285-92. DOI: 10.1001/archinte.164.12.1285. View

18.

Khot U, Khot M, Bajzer C, Sapp S, Ohman E, Brener S . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7):898-904. DOI: 10.1001/jama.290.7.898. View

19.

Murray G, Butcher I, Heald C, Lee R, Chambless L, Folsom A . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300(2):197-208. PMC: 2932628. DOI: 10.1001/jama.300.2.197. View

20.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View